FDA Approved KEYTRUDA For Treatment Of Patients With Resectable (T≥4 cm or N+) NSCLC In Combination With Chemotherapy As Neoadjuvant Treatment, Then Continued As A Single Agent As Adjuvant Treatment After Surgery
Portfolio Pulse from Charles Gross
The U.S. Food and Drug Administration (FDA) has approved Merck's (NYSE:MRK) anti-PD-1 therapy, KEYTRUDA, for the treatment of patients with resectable non-small cell lung cancer (NSCLC). The approval is based on data from the Phase 3 KEYNOTE-671 trial, which showed significant improvements in event-free survival (EFS) and overall survival (OS).
October 16, 2023 | 11:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's KEYTRUDA has received FDA approval for the treatment of resectable NSCLC, potentially increasing the company's market share in the oncology sector.
FDA approval of a new indication for KEYTRUDA expands Merck's potential customer base, which could lead to increased sales and positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100